The prognostic value of a 4-factor neoimmunologic score system in non-small cell lung cancer
The prognostic value of a 4-factor neoimmunologic score system in non-small cell lung cancer
复制标题
DOI：
10.1002/jlb.5ma0722-757rrr
复制
发表时间：
2022-09-08
影响因子：
5.5
通讯作者：
Ren，Xiubao
中科院分区：
文献类型：
--
作者：
Yang，Fan;Zeng，Ziqing;Ren，Xiubao
不同免疫细胞类型在调节癌症进展中的作用最近引起了人们的关注。免疫环境通过基于肿瘤核心 (CT) 和浸润性肿瘤边缘 (IM) 中量化的淋巴细胞的丰富免疫浸润来指示。新型免疫生物标志物可能会补充非小细胞肺癌（NSCLC）的肿瘤淋巴结转移（TNM）分类，从而提高预后准确性。本研究评估了新建立的免疫评分 (neo-IS) 对 NSCLC 患者的预后价值。我们使用免疫组织化学 (IHC) 在 2 个队列的 350 名 NSCLC 患者中检测到了 10 种免疫生物标志物，包括 CD45RO、CD3、CD8、CD68、CD163、CD66b、FoxP3、PD-1、PD-L1 和 TIM-3。评估了 3 年和 5 年生存率以及总生存率 (OS)。使用 Cox 比例风险回归模型构建了专门针对 NSCLC 患者的免疫学预测模型，即新免疫学评分 (neo-ISNSCLC)。在发现队列 (n= 250) 中，新 ISNSCLC 的建立基于 4 种免疫生物标志物：CD3+IM、CD8+CT、FoxP3+IM 和 PD-1+IM。比较低 ISNSCLC 患者和高 ISNSCLC 患者发现显着的预后差异。高 ISNSCLC 组的 OS 率显着长于低 ISNSCLC 组（67.5 个月 vs. 51.2 个月，p< 0.001）。新 ISNSCLC 在验证队列 (n= 100) 中进行了验证，结果得到证实。多变量分析表明neo-ISNSCLC是NSCLC患者预后的独立指标。最后，我们将neo-ISNSCLC与临床病理因素相结合，建立了供临床使用的肿瘤-淋巴结-转移-免疫（TNM-I）分期系统，该系统比TNM分期具有更好的预测准确性。
The role of distinct immune cell types in modulating cancer progression has recently gained attention. The immune context is indicated by the abundance of immune infiltration based on quantified lymphocytes in the core of tumors (CT) and invasive tumor margin (IM). Novel immune biomarkers could potentially complement tumor-node-metastasis (TNM) classification for non-small cell lung cancers (NSCLCs), thereby improving prognostic accuracy. This study evaluated the prognostic value of a newly established immunologic score (neo-IS) in patients with NSCLC. We detected 10 immune biomarkers, including CD45RO, CD3, CD8, CD68, CD163, CD66b, FoxP3, PD-1, PD-L1, and TIM-3, in 350 patients with NSCLC from 2 cohorts using immunohistochemistry (IHC). The 3- and 5-year survival and overall survival (OS) rates were evaluated. An immunologic prediction model specifically for NSCLC patients, the neo-immunologic score (neo-ISNSCLC), was constructed using a Cox proportional hazards regression model. In the discovery cohort (n= 250), the establishment of neo-ISNSCLCwas based on 4 immune biomarkers: CD3+IM, CD8+CT, FoxP3+IM, and PD-1+IM. Significant prognostic differences were found upon comparing low-ISNSCLCpatients and high-ISNSCLCpatients. The OS rate in the high-ISNSCLCgroup was significantly longer than that in the low-ISNSCLCgroup (67.5 months vs. 51.2 months,p< 0.001). The neo-ISNSCLCwas validated in the validation cohort (n= 100), and the results were confirmed. Multivariate analyses indicated that neo-ISNSCLCwas an independent indicator of prognosis in patients with NSCLC. Finally, we combined neo-ISNSCLCwith clinicopathologic factors to establish a tumor-node-metastasis-immune (TNM-I) staging system for clinical use, which showed better prediction accuracy than the TNM stage.